CAMBRIDGE, Mass. – January 5, 2010 – Selventa^TM, which evolved from Genstruct®, Inc. today announced the availability of the latest release of their high-performance analytical software tools. Selventa’s Hypothesis Investigation Suite and the Model Investigation Suite contain an interoperable set of applications that support integrated workflows for generating and investigating key biological mechanisms derived from large volumes of experimental data. These suites, available as bundled products and individual modular applications, now are available as web-accessible licensed software programs for Selventa’s academic, pharmaceutical and biotechnology partners.

Derived from the Genstruct® Technology Platform, Selventa’s key technology, these application suites have been modified and enhanced to provide an extended set of high-performance analytical tools using a Software as a Service (SaaS) delivery model. The Hypothesis Investigation Suite contains the Project Manager and Project Workbench applications, which enable rapid loading of large volumes of experimental data and the ability to generate and analyze mechanistic hypotheses. The Model Investigation Suite contains the Model Viewer, Model Analyzer and Model Editor applications, which provides users with an integrated set of powerful tools for building, analyzing and reporting explanatory biological models and their interactions.

“The SaaS delivery method simplifies access to the applications for our existing customers with whom our scientists collaborate daily,” said David de Graaf, President and CEO of Selventa. “These solutions will greatly enhance our customers’ internal scientific efforts by empowering them with direct access to the technology that advances their own scientific research programs. Offering these licensed software products fully enables our customers and collaborators to gain the most value out of their in-house data and engagements with Selventa.”

About Selventa

Founded in 2002 and privately-held, Selventa helps clients find optimal treatments for the right patients by offering scientific consulting services, licensed software products and strategic partnerships. The company analyzes rich patient data, accelerates the development process and clarifies decisions on therapeutics and diagnostics. Selventa engages in short-, mid- and long-term relationships with top-tier pharmaceutical and life science companies to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases, inflammation and drug safety. For more information, visit www.selventa.com.

Contact:

Diane H. Song, Ph.D., 617-547-5421 x235
dsong@selventa.com

Paul Kidwell, 617-296-3854
paulkidwell@comcast.net